Vertex announces update to U.S. prescribing information for INCIVEK Vertex Pharmaceuticals announced that the INCIVEK label in the United States has been updated to include a Boxed Warning stating that fatal and non-fatal serious skin reactions have been reported in patients taking INCIVEK combination treatment. Fatal cases of serious skin reactions have been reported in patients with progressive rash and systemic symptoms who continued to receive INCIVEK combination treatment after a serious skin reaction was identified. In Phase 3 clinical trials, less than 1% of people who received INCIVEK combination treatment experienced a serious skin reaction. These serious skin reactions required hospitalization and all patients recovered. The INCIVEK label was also updated to include additional information on the time to onset and management of anemia.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Vertex shares should be owned ahead of data, says JMP Securities JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.